These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 35654625)

  • 1. Discovery of novel Glutaminase allosteric inhibitors through drug repurposing and comparative MMGB/PBSA and molecular dynamics simulation.
    Yousaf R; Navid A; Azam SS
    Comput Biol Med; 2022 Jul; 146():105669. PubMed ID: 35654625
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Structure-Enabled Discovery of Novel Macrocyclic Inhibitors Targeting Glutaminase 1 Allosteric Binding Site.
    Xu X; Wang J; Wang M; Yuan X; Li L; Zhang C; Huang H; Jing T; Wang C; Tong C; Zhou L; Meng Y; Xu P; Kou J; Qiu Z; Li Z; Bian J
    J Med Chem; 2021 Apr; 64(8):4588-4611. PubMed ID: 33792311
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Identification and characterization of a novel glutaminase inhibitor.
    Cederkvist H; Kolan SS; Wik JA; Sener Z; Skålhegg BS
    FEBS Open Bio; 2022 Jan; 12(1):163-174. PubMed ID: 34698439
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Computational repurposing approach for targeting the critical spike mutations in B.1.617.2 (delta), AY.1 (delta plus) and C.37 (lambda) SARS-CoV-2 variants using exhaustive structure-based virtual screening, molecular dynamic simulations and MM-PBSA methods.
    Ebrahimi M; Karami L; Alijanianzadeh M
    Comput Biol Med; 2022 Aug; 147():105709. PubMed ID: 35728285
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prediction of novel inhibitors for
    Khedrinia M; Aryapour H; Mianabadi M
    Drug Chem Toxicol; 2021 Sep; 44(5):470-479. PubMed ID: 31668098
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Development and Characterization of a Fluorescent Probe for GLS1 and the Application for High-Throughput Screening of Allosteric Inhibitors.
    Xu X; Kuang Z; Han J; Meng Y; Li L; Luan H; Xu P; Wang J; Luo C; Ding H; Li Z; Bian J
    J Med Chem; 2019 Nov; 62(21):9642-9657. PubMed ID: 31603674
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In silico investigations on the binding efficacy and allosteric mechanism of six different natural product compounds towards PTP1B inhibition through docking and molecular dynamics simulations.
    SarathKumar B; Lakshmi BS
    J Mol Model; 2019 Aug; 25(9):272. PubMed ID: 31451955
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Design and synthesis of novel tellurodibenzoic acid compounds as kidney-type glutaminase (KGA) inhibitors.
    Hou W; Zhou Y; Rui J; Bai R; Bhasin AKK; Ruan BH
    Bioorg Med Chem Lett; 2019 Jul; 29(13):1673-1676. PubMed ID: 31076348
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Characterization of the interactions of potent allosteric inhibitors with glutaminase C, a key enzyme in cancer cell glutamine metabolism.
    Huang Q; Stalnecker C; Zhang C; McDermott LA; Iyer P; O'Neill J; Reimer S; Cerione RA; Katt WP
    J Biol Chem; 2018 Mar; 293(10):3535-3545. PubMed ID: 29317493
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Discovery and optimization of withangulatin A derivatives as novel glutaminase 1 inhibitors for the treatment of triple-negative breast cancer.
    Zhou WX; Chen C; Liu XQ; Li Y; Lin YL; Wu XT; Kong LY; Luo JG
    Eur J Med Chem; 2021 Jan; 210():112980. PubMed ID: 33176943
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Design, synthesis, structure-activity relationship studies, and evaluation of novel GLS1 inhibitors.
    Jo M; Koizumi K; Suzuki M; Kanayama D; Watanabe Y; Gouda H; Mori H; Mizuguchi M; Obita T; Nabeshima Y; Toyooka N; Okada T
    Bioorg Med Chem Lett; 2023 May; 87():129266. PubMed ID: 37011768
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Structure-based virtual screening discovers novel kidney-type glutaminase inhibitors.
    Lin LC; Chang HY; Lin TE; Lin JR; Hsia SM; Hsu KC; Huang TC
    Biomed Pharmacother; 2022 Oct; 154():113585. PubMed ID: 36029536
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Design, Synthesis, and Evaluation of Thiazolidine-2,4-dione Derivatives as a Novel Class of Glutaminase Inhibitors.
    Yeh TK; Kuo CC; Lee YZ; Ke YY; Chu KF; Hsu HY; Chang HY; Liu YW; Song JS; Yang CW; Lin LM; Sun M; Wu SH; Kuo PC; Shih C; Chen CT; Tsou LK; Lee SJ
    J Med Chem; 2017 Jul; 60(13):5599-5612. PubMed ID: 28609101
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Structural basis for the allosteric inhibitory mechanism of human kidney-type glutaminase (KGA) and its regulation by Raf-Mek-Erk signaling in cancer cell metabolism.
    Thangavelu K; Pan CQ; Karlberg T; Balaji G; Uttamchandani M; Suresh V; Schüler H; Low BC; Sivaraman J
    Proc Natl Acad Sci U S A; 2012 May; 109(20):7705-10. PubMed ID: 22538822
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Overview of the Development of Glutaminase Inhibitors: Achievements and Future Directions.
    Xu X; Meng Y; Li L; Xu P; Wang J; Li Z; Bian J
    J Med Chem; 2019 Feb; 62(3):1096-1115. PubMed ID: 30148361
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pan-Cancer Metabolic Signature Predicts Co-Dependency on Glutaminase and De Novo Glutathione Synthesis Linked to a High-Mesenchymal Cell State.
    Daemen A; Liu B; Song K; Kwong M; Gao M; Hong R; Nannini M; Peterson D; Liederer BM; de la Cruz C; Sangaraju D; Jaochico A; Zhao X; Sandoval W; Hunsaker T; Firestein R; Latham S; Sampath D; Evangelista M; Hatzivassiliou G
    Cell Metab; 2018 Sep; 28(3):383-399.e9. PubMed ID: 30043751
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeting glutaminase 1 attenuates stemness properties in hepatocellular carcinoma by increasing reactive oxygen species and suppressing Wnt/beta-catenin pathway.
    Li B; Cao Y; Meng G; Qian L; Xu T; Yan C; Luo O; Wang S; Wei J; Ding Y; Yu D
    EBioMedicine; 2019 Jan; 39():239-254. PubMed ID: 30555042
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Identification of novel potential ricin inhibitors by virtual screening, molecular docking, molecular dynamics and MM-PBSA calculations: a drug repurposing approach.
    Botelho FD; Santos MC; Gonçalves AS; França TCC; LaPlante SR; de Almeida JSFD
    J Biomol Struct Dyn; 2022 Aug; 40(12):5309-5319. PubMed ID: 33410376
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Discovery of selective inhibitors of Glutaminase-2, which inhibit mTORC1, activate autophagy and inhibit proliferation in cancer cells.
    Lee YZ; Yang CW; Chang HY; Hsu HY; Chen IS; Chang HS; Lee CH; Lee JC; Kumar CR; Qiu YQ; Chao YS; Lee SJ
    Oncotarget; 2014 Aug; 5(15):6087-101. PubMed ID: 25026281
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Computer-assisted discovery of safe and effective DprE1/ aaRSs Inhibitors against TB utilizing Drug Repurposing approach.
    Imran M; Abida ; Alotaibi NM; Thabet HK; Alruwaili JA; Asdaq SMB; Eltaib L; Kamal M; Alshammari ABH; Alshammari AMA; Alshehri A
    J Infect Public Health; 2023 Apr; 16(4):554-572. PubMed ID: 36812878
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.